FN rates in the main trials of association between chemotherapy and immunotherapy
| Trial | Cancer type | Drugs | FN: chemotherapy+immunotherapy arm | FN: chemotherapy arm | G-CSF or GM-CSF use |
| KEYNOTE-407 | NSCLC squamous | Pembrolizumab+carboplatin+(nab)-paclitaxel | 5.4% | 3.6% | Permitted as for guidelines |
| KEYNOTE-189 | NSCLC non-squamous | Pembrolizumab+cis- or carboplatin+pemetrexed | 5.7% | 2.0% | Permitted as for guidelines |
| IMpower133 | SCLC | Atezolizumab+carboplatin+etoposide | 2.5% | 4.4% | NA |
| KEYNOTE-048 | HNSCC | Pembrolizumab+cis- or carboplatin+5-fluorouracil | 6.2% | 5.2% | Permitted as for guidelines |
| IMpassion130 | Breast cancer | Atezolizumab+nab-paclitaxel | 1.9% | 2.2% | NA |
FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HNSCC, head and neck squamous cell carcinoma; NA, not available; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.